

Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *cell*, 86(3), 353-364.

Hanahan, D., Christofori, G., Naik, P., & Arbeit, J. (1996). Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. *European Journal of Cancer*, 32(14), 2386-2393.

Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997). Interstitial pH and pO<sub>2</sub> gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. *Nature medicine*, 3(2), 177-182.

Herbst, R. S., Hess, K. R., Tran, H. T., Tseng, J. E., Mullani, N. A., Charnsangavej, C., ... & Abbruzzese, J. L. (2002). Phase I study of recombinant human endostatin in patients with advanced solid tumors. *Journal of Clinical Oncology*, 20(18), 3792-3803.

Hidalgo, M., & Eckhardt, S. G. (2001). Development of matrix metalloproteinase inhibitors in cancer therapy. *Journal of the National Cancer Institute*, 93(3), 178-193.

Hiraoka, N., Allen, E., Apel, I. J., Gyetko, M. R., & Weiss, S. J. (1998). Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. *Cell*, 95(3), 365-377.

Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Di Maria, M. V., Veve, R., Bremnes, R. M., ... & Franklin, W. A. (2003). Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. *Journal of Clinical Oncology*, 21(20), 3798-3807.